Thanks. This depression indication is another reminder of the frustrations we've had with these euro-sloth partners. Servier and Organon, what a pair.
Can you imagine: you have a compound that could possibly be given in combo therapy with existing antipsychotics to relieve negative symptoms of schizo. What do you do with it? Nothing. You have a compound that possibly could treat depression without a 6 week lag. What to you do with it? Nothing.
And that's just Oraganon. Servier did so little they finally had to return all the rights.
Market Data 
Markets 
AI
